MIRM at a glance
Mirum Pharmaceuticals, Inc. (MIRM, SEC CIK 1759425) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $521.3 million (up 54.7% from FY2024) and a net loss of $23.4 million. Diluted EPS was -$0.47.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Mirum Pharmaceuticals, Inc. (MIRM) shares worth $2.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Ramasastry Saira on November 16, 2026 of 2,000 shares at $92.28 per share.
- In the last 90 days, MIRM insiders reported 0 open-market purchases ($0) and 8 open-market sales ($7.3M) on Form 4, a net sale of $7.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $521.3M
- +54.7% vs prior year
- Insiders · 90 days
- 0 buys · 8 sells
- Net −$7.3M
- 13F holders
- 29 funds
- $2.0B · −1 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core biopharma focused on rare diseases with three approved medicines: Livmarli, Cholbam, Ctexli
- Acquired asset portfolios in 2023-2026: Travere’s bile acid medicines and Bluejay’s brelovitug for hepatitis D treatment
- Strategic expansion into chronic HDV with brelovitug advancing in global Phase 3 AZURE program, topline data expected H2 2026
- Livmarli approved in multiple countries for ALGS and PFIC; pursuing expanded indications with EXPAND Phase 3 study (results Q4 2026)
- Brelovitug Phase 2 showed 100% virologic response at 48 weeks, granted FDA Breakthrough and EMA PRIME designations
Risk Factors
- Regulatory risk CREATES Act compliance, sample provision obligations for generics under December 2019 law
- Geopolitical/macro exposure in EU and U.S. orphan drug exclusivity potentially shortened by EU legislative proposals
- Operational risk integration of Bluejay assets/employees critical to brelovitug development, potential disruption if integration fails
- Competitive risk several companies including Shionogi and Harmony Biosciences developing therapies for fragile X syndrome
- Financial risk dependence on key personnel amid fierce competition for talent in Foster City, CA with 369 full-time employees
AI summary of the MIRM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $185.7M, up $52.7M YoY from $133.0M
- Net loss $40.8M vs $2.9M net income; operating margin -32.2% vs 2.0%
- Best performer Livmarli: $133.4M, up $41.2M; Bile Acid Medicines $52.3M, up $11.5M
- Cash, equivalents and investments $500.5M vs $391.4M at December 31, 2025; nine-month operating cash flow -$277.3M
- Outlook: cash sufficient through at least next 12 months; continued net losses and higher brelovitug development spending expected
Risk Factors
- New regulatory risk: July 2026 FDA Form 483 cited untimely expedited adverse-event reports by Mirum and its pharmacovigilance vendor
- Most material update: FDA recommended a Phase 3 volixibat PSC study, delaying the planned NDA submission based on VISTAS data
- Market-access risk: Medicare negotiation, Most-Favored-Nation pricing proposals and German orphan-drug threshold reduction to €30 million
- Competitive risk: LIVMARLI generic ANDA filings triggered four 2025 patent complaints and a 2026 tablet litigation
- Financial risk: nine-month 2026 net loss $898.1 million, accumulated deficit $1.6 billion as continued losses are expected
AI summary of the MIRM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- AZURE-4 met its Week 24 primary endpoint: 59% at 300 mg QW and 44% at 900 mg Q4W versus 0% delayed treatment
- Positive result completes the second Phase 3 study supporting brelovitug’s planned U.S. registration package
Item 2.02: Results of Operations and Financial Condition
- Mirum announced financial results for the quarter ended September 30, 2026
- Corporate update released alongside quarterly results
Item EX-99.1: Item EX-99.1
- Q3 net product sales $185.7M, up from $133.0M, with 2026 guidance raised to $715M-$720M
- LIVMARLI sales $133.4M, up 45% year over year, while Bile Acid Medicines sales reached $52.3M, up 28%
Item 8.01: Other Events
- Positive Cohort 2 results in 25 children support expanding ATEBRIOZ approval to ages 6 to <12
- HO lesion volume fell 8.09 cm³ with zilurgisertib versus a 9.14 cm³ increase with placebo, nominal p=0.003
AI summaries of MIRM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MIRM
Don't miss the next MIRM filing
- Alerts as it files. A push when MIRM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MIRM, by share count.
- Ask anything. An AI agent that reads every MIRM filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ramasastry Saira | Sell | Nov 16, 2026 | 2,000 | $92.28 |
| Ramasastry Saira | M | Nov 16, 2026 | 2,000 | - |
| Ramasastry Saira | M | Nov 16, 2026 | 2,000 | $28.97 |
| Brege Laura | Sell | Nov 11, 2026 | 10,907 | $94.05 |
| Brege Laura | M | Nov 11, 2026 | 14,167 | $16.71 |
| Brege Laura | M | Nov 11, 2026 | 14,167 | - |
| Brege Laura | Sell | Nov 11, 2026 | 3,260 | $94.74 |
| Peetz Christopher | Sell | Nov 4, 2026 | 20,000 | $90.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $336.9M | $521.3M |
| Operating Income | - | -$87.6M | -$22.1M |
| Net Income | -$163.4M | -$87.9M | -$23.4M |
| Op. Margin | - | -26.0% | -4.2% |
| Net Margin | - | -26.1% | -4.5% |
| Balance Sheet | |||
| Total Assets | - | $670.8M | $842.8M |
| Equity | $248.7M | $225.6M | $314.7M |
| ROE | -65.7% | -39.0% | -7.4% |
| Per Share | |||
| EPS | $-4.00 | $-1.85 | $-0.47 |
| Cash Flow | |||
| Operating CF | - | $10.3M | $55.8M |
| CapEx | $109K | $993K | $954K |
Source: XBRL data in Mirum Pharmaceuticals, Inc. (MIRM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MIRM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $2.01B |
| Q2 2026 | 30 | $2.96B |
| Q1 2026 | 31 | $1.94B |
| Q4 2025 | 26 | $1.36B |
| Q3 2025 | 28 | $1.22B |
| Q2 2025 | 27 | $818.9M |
| Q1 2025 | 24 | $486.8M |
| Q4 2024 | 19 | $339.0M |
- BlackRock+333.2K (+8%)
- Vanguard Portfolio Management LLC+256.6K (+11%)
- Vanguard Capital Management LLC+244.4K (+11%)
- State Street Corp+220.0K (+10%)
- Ameriprise Financial+174.0K (+24%)
- Goldman Sachs Group−174.1K (-32%)
- T. Rowe Price Group−111.2K (-4%)
- Renaissance Technologies LLC−80.8K (-18%)
- Principal Financial Group−52.8K (-52%)
- Citigroup−37.0K (-22%)
- Citadel Advisors LLC+98.2K
- Dimensional Fund Advisors+14.3K
- FMR LLC (Fidelity)−3.67M
- Mangrove Partners−9.9K
- Marex Group plc−3.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 214 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MIRM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 8-K | Oct 26, 2026 | - | Analysis | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MIRM SEC filings: frequently asked questions
Are MIRM insiders buying or selling?
In the last 90 days, Mirum Pharmaceuticals, Inc. (MIRM) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $7.3 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MIRM stock?
As of September 30, 2026, the largest Mirum Pharmaceuticals, Inc. (MIRM) holders among the 13F filers tracked by SignalX were BlackRock ($403.7 million), Vanguard Portfolio Management LLC ($225.1 million), T. Rowe Price Group ($217.5 million), Vanguard Capital Management LLC ($213.6 million), State Street Corp ($204.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MIRM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $521.3 million (up 54.7% from FY2024) and a net loss of $23.4 million. Diluted EPS was -$0.47. The figures come from the XBRL data in the 10-K.
What are the main risks in MIRM's latest 10-K?
In the 10-K filed February 25, 2026, Mirum Pharmaceuticals, Inc. (MIRM) flagged: Regulatory risk CREATES Act compliance, sample provision obligations for generics under December 2019 law. Geopolitical/macro exposure in EU and U.S. orphan drug exclusivity potentially shortened by EU legislative proposals. (AI summary of the Risk Factors section.)
What did MIRM report in its latest 8-K?
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K on November 10, 2026 reporting Item 8.01 (Other Events). AZURE-4 met its Week 24 primary endpoint: 59% at 300 mg QW and 44% at 900 mg Q4W versus 0% delayed treatment.
What are the latest MIRM SEC filings?
Mirum Pharmaceuticals, Inc. (MIRM) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 17, 2026.
What is MIRM's SEC CIK number?
Mirum Pharmaceuticals, Inc. (MIRM)'s SEC Central Index Key (CIK) is 1759425. EDGAR lists every MIRM filing under that number.
Ask anything about MIRM
The research agent reads MIRM's filings, financials, insider trades and 13F holders, then answers with sources.